IDEXX Laboratories (IDXX) Earnings Analysis
IDEXX Laboratories (IDXX) has no confirmed upcoming earnings date. Last quarter (2026-02-02) it beat with EPS 3.08 USD vs 2.93 USD est (+5.1%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E 39.87.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does IDXX next report earnings?
No confirmed upcoming earnings date is currently scheduled for IDXX. This page updates as the calendar is published.
IDXX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-02 | 3.08 USD | 2.93 USD | +5.1% | Beat |
| 2025-11-03 | 3.4 USD | 3.14 USD | +8.3% | Beat |
| 2025-08-04 | 3.63 USD | 3.28 USD | +10.7% | Beat |
| 2025-05-01 | 2.96 USD | 2.85 USD | +3.9% | Beat |
| 2025-02-03 | 2.62 USD | 2.39 USD | +9.6% | Beat |
| 2024-10-31 | 2.8 USD | 2.68 USD | +4.5% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
IDXX valuation and analyst view
| Trailing P/E | 39.87 |
|---|---|
| Trailing EPS | 13.674 USD |
| Price / book | 28.05 |
| Dividend yield | 0.00% |
| Market cap | 43.29B |
| Analyst consensus | Buy (13 buy / 8 hold / 1 sell) |
| Avg price target | 640 USD |
Related research pages
Frequently asked questions
When is IDEXX Laboratories (IDXX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for IDXX. This page updates as the calendar is published.
Did IDXX beat earnings last quarter?
In its 2026-02-02 report, IDXX posted EPS of 3.08 USD versus a 2.93 USD estimate — a beat of 5.1%.
What is IDXX's earnings track record?
Over the last 6 reported quarters with consensus data, IDXX beat estimates 6 times (100%).
What is IDXX's current P/E ratio and EPS?
IDXX trades at a trailing P/E of 39.87 on trailing EPS of 13.674003695565322 USD.
What do analysts rate IDXX?
Analyst consensus is "Buy" across 22 ratings (0 strong buy, 13 buy, 8 hold, 1 sell, 0 strong sell). Average 12-month price target: 640 USD.